
Arnaud Del Bello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8672641/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. New England Journal of Medicine, 2021, 385, 661-662.	27.0	728
2	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. American Journal of Transplantation, 2016, 16, 2816-2835.	4.7	451
3	Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Annals of Internal Medicine, 2021, 174, 1336-1338.	3.9	122
4	Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 322-323.	4.7	120
5	Prevalence, Incidence and Risk Factors for Donor-Specific Anti-HLA Antibodies in Maintenance Liver Transplant Patients. American Journal of Transplantation, 2014, 14, 867-875.	4.7	96
6	High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrology Dialysis Transplantation, 2021, 36, 1704-1709.	0.7	87
7	Donor-Specific Antibodies after Ceasing Immunosuppressive Therapy, with or without an Allograft Nephrectomy. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1310-1319.	4.5	77
8	<i>De novo</i> donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transplant International, 2015, 28, 1371-1382.	1.6	70
9	Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation. Transplantation, 2016, 100, 159-166.	1.0	59
10	Successful treatment of hepatitis E virusâ€associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin. Transplant Infectious Disease, 2015, 17, 279-283.	1.7	55
11	Donor-specific antibodies and liver transplantation. Human Immunology, 2016, 77, 1063-1070.	2.4	44
12	Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients. American Journal of Transplantation, 2022, 22, 1467-1474.	4.7	37
13	Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?. American Journal of Transplantation, 2021, 21, 1641-1649.	4.7	26
14	Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. Advances in Therapy, 2019, 36, 462-477.	2.9	25
15	Early Administration of Anti–SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients. Kidney International Reports, 2022, 7, 1241-1247.	0.8	25
16	Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients. Transplantation Direct, 2022, 8, e1248.	1.6	25
17	Improved Fetal Hemoglobin With mTOR Inhibitor–Based Immunosuppression in a Kidney Transplant Recipient With Sickle Cell Disease. American Journal of Transplantation, 2017, 17, 2212-2214.	4.7	24
18	Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy. Emerging Infectious Diseases, 2019, 25, 2145-2147.	4.3	24

Arnaud Del Bello

#	Article	IF	CITATIONS
19	Preemptive second kidney transplantation is associated with better graft survival compared with non-preemptive second transplantation: a multicenter French 2000-2014 cohort study. Transplant International, 2018, 31, 408-423.	1.6	22
20	Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. Annals of Internal Medicine, 2020, 173, 501-503.	3.9	21
21	Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. American Journal of Transplantation, 2020, 20, 1365-1374.	4.7	20
22	Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results. Transplant Immunology, 2015, 32, 151-155.	1.2	18
23	Outcome of Liver Transplant Patients With Preformed Donorâ€5pecific Anti–Human Leukocyte Antigen Antibodies. Liver Transplantation, 2020, 26, 256-267.	2.4	17
24	Histological longâ€ŧerm outcomes from acute antibodyâ€mediated rejection following ABOâ€compatible liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 887-893.	2.8	13
25	Outcomes of solid organ transplant recipients with invasive aspergillosis and other mold infections. Transplant Infectious Disease, 2020, 22, e13200.	1.7	9
26	Primary hyperoxaluria type 2 successfully treated with combined liver-kidney transplantation after failure of isolated kidney transplantation. American Journal of Transplantation, 2020, 20, 1752-1753.	4.7	9
27	Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors. Journal of Hepatology, 2014, 61, 963-965.	3.7	8
28	Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. Case Reports in Transplantation, 2017, 2017, 1-6.	0.3	8
29	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. American Journal of Transplantation, 2021, 21, 3021-3033.	4.7	8
30	Cytokine storm induced by a PD1 inhibitor in a renal transplant patient. American Journal of Transplantation, 2021, 21, 2616-2618.	4.7	8
31	Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine. Vaccines, 2022, 10, 354.	4.4	8
32	Recurrence of oxalate nephropathy after isolated kidney transplantation for primary hyperoxaluria type 2. American Journal of Transplantation, 2018, 18, 525-526.	4.7	7
33	Specific organization for in-hospital belatacept infusion to avoid nosocomial transmission during the SARS-CoV-2 pandemic. American Journal of Transplantation, 2020, 20, 2962-2963.	4.7	7
34	Combined Liver-Kidney Transplantation With Preformed Anti–human Leukocyte Antigen Donor-Specific Antibodies. Kidney International Reports, 2020, 5, 2202-2211.	0.8	6
35	Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. Journal of Transplantation, 2015, 2015, 1-5.	0.5	5
36	Fatal encephalitis and Borna Disease Virusâ€1 seropositivity in two kidneyâ€transplant patients living in the same nonendemic area. Transplant Infectious Disease, 2021, 23, .	1.7	5

Arnaud Del Bello

#	Article	IF	CITATIONS
37	Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial. American Journal of Transplantation, 2022, 22, 1430-1441.	4.7	5
38	Maintaining immunosuppressive treatment after early allograft nephrectomy does not reduce the risk of anti-HLA allosensitization. Transplant International, 2015, 28, 1113-1115.	1.6	4
39	Antiâ€ILâ€2R blockers comparing with polyclonal antibodies: Higher risk of rejection without negative midâ€term outcomes after ABOâ€incompatible kidney transplantation. Clinical Transplantation, 2019, 33, e13681.	1.6	4
40	No evidence of occult hepatitis C or E virus infections in liverâ€ŧransplant patients with sustained virological response after therapy with direct acting agents. Transplant Infectious Disease, 2019, 21, e13093.	1.7	4
41	T cell reconstitution after lymphocyte depletion features a different pattern of inhibitory receptor expression in ABO―versus HLAâ€incompatible kidney transplant recipients. Clinical and Experimental Immunology, 2020, 200, 89-104.	2.6	4
42	Kidney transplantation during the COVIDâ€19 pandemic: Potential longâ€term consequences of an early postâ€transplant infection. Transplant Infectious Disease, 2021, 23, e13446.	1.7	4
43	Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of nonâ€melanoma skin cancer after kidney transplantation, a pilot study. Clinical Transplantation, 2021, 35, e14207.	1.6	4
44	Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. Kidney International, 2021, 100, 915-927.	5.2	4
45	Impact of calcineurin inhibitorâ€free immunosuppression on de novo donorâ€specific antibody formation in liver transplant recipients. Liver International, 2022, 42, 1132-1143.	3.9	4
46	Impact of transplant accessibility for sensitized patients by avoiding unacceptable antigens. Liver Transplantation, 2017, 23, 880-886.	2.4	3
47	The CD226/TIGIT axis is involved in T cell hypo-responsiveness appearance in long-term kidney transplant recipients. Scientific Reports, 2022, 12, .	3.3	2
48	Possible patient to patient transmission of progressive multifocal leukoencephalopathy among kidney-transplant patients. Brazilian Journal of Infectious Diseases, 2020, 24, 473-474.	0.6	1
49	A Randomized Prospective Study Comparing Anti–T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients. Kidney International Reports, 2020, 5, 1207-1217.	0.8	1